Inclusion Criteria:  ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1 pathologically proven primary gastric adenocarcinoma peritoneal metastasis confirmed by laparoscopy or diagnostic imaging written informed consent adequate function of important organs (within 14 days before registration)  Absolute neutrophil count ≥1.5 x 10^9/L, Platelet >=100,000/mm3, Hemoglobin >=8.0g/dL, Total bilirubin <= ≤ 2.0mg/dl or ULN(Upper Limit of Normal) x 1.5, AST(aspartate aminotransferase) <=100IU/L(International Unit/Liter), ALT(alanine transaminase) <=100IU/L, Creatinine clearance ≥ 50mL/min (milliliter/minute),  Exclusion Criteria:  other active concomitant malignancies HER2(human epidermal growth factor receptor 2) positive (Immunohistochemistry 3+ or 2+ with in situ hybridization positive) no investigational anticancer therapy within 30 days prior to the first dose of study treatment recent (within 6 months) acute coronary syndrome, severe heart failure or severe pulmonary disease uncontrolled acute or chronic disease uncontrolled infection or inflammation uncontrolled psychiatric disorder or central neurologic disease not fully recovered from previous surgery prior anticancer therapy (chemotherapy, immunotherapy, radiation) within 6 months intolerable to oral administration or a lack of physical integration of the upper gastrointestinal tract or with a malabsorption syndrome fertile males and females who are unwilling to use effective contraceptive methods. pregnancy, breast feeding or intention to become pregnant interstitial pneumonia or pulmonary fibrosis peripheral neuropathy with functional impairment hypersensitivity to paclitaxel, oxaliplatin, capecitabine, fluoropyrimidine or Cremophor EL. concomitant therapy with any substrate or inhibitor of Cytochrome P450 2C8 or 3A4 concomitant therapy with sorivudine or brivudine Dihydropyrimidine dehydrogenase (DPD) deficiency. current or recent (within the 7 days prior to enrollment) treatment of tegafur-gimeracil-oteracil potassium